Amedisys (AMED) Tops Q4 EPS by 6c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amedisys (AMED) PT Lowered to $124 at Craig-Hallum
February 28, 2019 3:52 PM ESTCraig-Hallum analyst Kevin Ellich lowered the price target on Amedisys (NASDAQ: AMED) to $124.00 (from $132.00) while maintaining a Hold rating.
Ellich notes FY19 guidance was lower partially due to CCH integration.
... More